Previous 10 | Next 10 |
Vor Biopharma (VOR) has priced its initial public offering of ~9.83M shares at $18/share, for gross proceeds of ~$176.9M.The company originally planned to offer 8.8M shares at a price range of $16-$18.Underwriters' over-allotment is an additional 1,474,202 shares. Shares to kick-off trading t...
Sio Gene Therapies (SIOX) +42% on positive AXO-AAV-GM1 data in nerve cell disorder.Good Times Restaurants (GTIM) +27% on Q4 results.Tilray (TLRY) +27% as company to combine with Aphria to create largest global cannabis company.DAVIDsTEA (DTEA) +25% on Q3 results.NeuBa...
Cellectis (CLLS) has withdrawn its previous ADS offering due to market conditions and it is not in the best interest of its stockholders. Cash position of $308M at the end of Q3 will fund company's key programs into 2022.Previously: Cellectis initiates equity raise of $100M (Dec. 14) For fu...
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that it has withdrawn the proposed und...
Gainers: Anchiano Therapeutics (ANCN) +142%.BioCardia (BCDA) +87%.Prevail Therapeutics (PRVL) +81%.Solid Biosciences (SLDB) +36%.OncoCyte (OCX) +24%.Bridgetown (BTWN) +23%.Contango Oil & Gas (MCF) +22%.Immutep (IMMP) +22%.MicroVision (MVIS) +20%.Sio Gene Therapies (SIOX) +1...
Cellectis (CLLS) has launched an underwritten public offering of $100M of its American Depositary Shares, each representing one ordinary share of Cellectis. Underwriters have an option to purchase up to an additional 15% of the aggregate offering size.Price, number of shares are yet to be det...
NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells, today announced the launch, su...
Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease 2 out of 3 Patients at DL1 Achieved CR/CRi and 1 out of 2 Patients at DL2 Achieved a Significant Reduction in Bone Ma...
ARKG aims to capitalize on a $9Tn TAM with the convergence of AI, DNA Sequencing and Gene-Editing. ARKG is up 149% YTD vs. the SPX return of 13%. Led by Cathie Wood, I think ARKG will be the best performing ARK Fund over the next 10 years. For further details see: ARKG: ...
Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 months to further elucidate safety and efficacy. The combination of high clinical f...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...